mediated metabolic tumor effects using in vivo achievable biguanide concentrations. Materials and Methods: Initially we developed 11 C labeled MET, which allowed assessment of in vitro cellular drug uptake and, importantly, in vivo biodistribution assessment using PET scans or organ dissection in tumor-bearing mice. Based on those results cellular effects of physiologically relevant doses of biguanides were tested in 14 cell lines using assays of proliferation/viability, glucose metabolism (FDG retention), respiration and lactic acid production (extracellular flux analyzer) and stress signaling. Finally, the two tumor models SiHa (cervix) and A549 (lung) were established in mice to assess acute and long-term metabolic, microenvironmental and anti-proliferative effects of PHEN treatment.
Results:
In vivo results showed that [MET] in blood peaked at 250 μM in mice administered maximum tolerable dose (250 mg/kg). Furthermore, MET was retained by tumor cells in vitro as well as in vivo, and uptake could be blocked by unlabeled MET suggesting involvement of OCTs. MET uptake varied widely among cell lines, with the highest uptake in A549. Likewise, inhibition of respiration and stimulation of glucose use and cell viability/proliferation was mostly affected in cell lines with high MET uptake. Even so, most cell lines were insensitive to in vivo achievable MET concentrations. PHEN was 100 times more potent than MET and induced profound metabolic changes at 50 μM in all cell lines, and down to a physiological relevant concentration of 1 μM in A549. In accordance, PHEN was chosen for further testing in tumor-bearing mice. Data analysis of tumor microenvironment (hypoxia) and growth is ongoing. Conclusions: Biguanides affect cellular energy metabolism and proliferation in vitro but metabolic effects of MET were typically restricted to non-physiological concentrations and MET retention and sensitivity varied significantly among cell lines. PHEN exerted similar effects as MET but with greater potency and may affect a broader selection of tumors at physiologically achievable concentrations. Labeling of biguanides may allow PET-based identification of patients with treatment-responsive tumors.
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Carbon ion irradiation response depends less on tumor heterogeneity: RBE-comparison for 3 prostate tumor sublines C. C-ions were determined for three sublines of a syngeneic rat prostate adenocarcinoma. Materials and Methods: Fresh tumor fragments from three sublines (AT1, HI and H) of the Dunning prostate tumor R3327 were transplanted subcutaneously into the distal right thigh of male Copenhagen rats. Tumors were treated once with increasing single doses of either 12 C-ions or 6 MeV photons. Primary endpoint was local tumor control within 300 days. For the H-tumor, histological tumor control, defined as absence of proliferation (BrdU-injection) in the remaining fibrotic nodules (Hematoxylin/Eosin staining) was used as secondary endpoint. RBE-values were calculated by the ratio of TCD 50 -values (dose to achieve 50% tumor control probability) for photons and 12 C-ions, respectively. Results: Local tumor control can be achieved with 12 C-ions and photons in all three sublines. For all tumors an increased effectiveness of 12 C-ions was observed. The RBE for local tumor control increased from 1.62 ± 0.11 (H) to 2.08 ± 0.13 (HI) to 2.30 ± 0.08 (AT1). Using histological tumor control, the RBE for the H-tumor increased to 1.80 ± 0.13. For 12 C-ion irradiations the variation of TCD 50 -values between tumor sublines was significantly smaller than after photon irradiation. Additionally 12 C-ion dose-response curves were much steeper compared to photons indicating a smaller intratumor heterogeneity for 12 C-ions.
Conclusions:
The study confirms the increased relative biological effectiveness of 12 C-ions in tumors, which is the highest for the highly radioresistant AT1-tumor and the smallest for the well-differentiated H-tumor. The very heterogeneous moderately differentiated HI-tumor lies in between. This indicates a clear correlation between decreasing differentiation status and increasing RBE.
12 C-ions may therefore be beneficial especially in undifferentiated tumors, with a high photon resistance. Changes of RBE with tumor differentiation were predominantly caused by changes in the photon response. This supports the assumption that the response to 12 C-ions is less dependent on tumor heterogeneity compared to photons. Thus heterogeneities within patient populations or the existence of radioresistant subpopulations within single tumors may be expected to have less impact on the 12 C-ions radiation response. The underlying differential mechanisms are currently analyzed in ongoing histological and functional experiments. 
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